Advertisement!
Author Information Pack
Editorial Board
Submit article
Special Issue
Editor's selection process
Join as Reviewer/Editor
List of Reviewer
Indexing Information
Most popular articles
Purchase Single Articles
Archive
Free Online Access
Current Issue
Recommend this journal to your library
Advertiser
Accepted Articles
Search Articles
Email Alerts
FAQ
Contact Us
Indian Journal of Genetics and Molecular Research

Volume  10, Issue 1, January–June 2021, Pages 9-14
 

Original Article

Evaluation and Characterization of Indian Chronic Myeloid Leukemia Patients on Imatinib

Sunita Chhikara 1, Sudha Sazawal 2, Rekha Chaubey 3, Manoranjan Mahapatra 4, Renu Saxena 5

1,3 Research Scientist, 2 Scientist, 4 Professor, Department of Hematology, All India Institute of Medical Sciences, New Delhi 110029, India. 5 HOD and Professor, Department of Hematology, Medanta Gurugram 122001, Haryana, India.

Choose an option to locate / access this Article:
90 days Access
Check if you have access through your login credentials.        PDF      |
|

Open Access: View PDF

DOI: http://dx.doi.org/10.21088/ijgmr.2319.4782.10121.1

Abstract

Background: Chronic myeloid leukemia (CML) is a clonal malignant disorder of hematopoietic stem cell characterized by the classical chromosomal translocation, Philadelphia (Ph) chromosome in more than 90% of the patients. CML is associated with significantly high granulocyte numbers in the bone marrow and peripheral blood. Materials and Methods: This is a retrospective study conducted at the All India Institute of Medical Sciences, New Delhi, India aimed to evaluate the incidence and characteristics of CML patients. We have evaluated the demographic, clinical, and hematological data of 158 consecutive patients who visited the hospital from 2012 to 2014. Results: The diagnosis and stage of CML were determined based on the World Health Organization criteria, followed by the polymerase chain reaction. 158 patients evaluated in this study, consist of males (n = 98, 62%) which was higher than females (n = 60, 38%)( M:F::1.6:1). The mean + SD of male and female was 35.6 + 12.7, mean + SD of males was ( 35.7+ 13.6) and mean + SD of females was ( 35.4+11.3). While 17 (10.7%) patients were below 20 years of age, 94 (59.4%) were between 21–40 years, 40 (25.3%) were between 41–60 years, and 7 (4.4%) were more than 60 years of age. The predominance of younger patients (59.4.%) were belong to the age group of 21-40 years. While the most predominant symptom was fatigue and bone pain, the most common clinical sign was hepato-splenomegaly, followed by remarkable weight loss, and epistaxis. Conclusion: A patient with an increased WBC count, weakness, bone pain, low LAP score and hepatosplenomegaly should clearly be evaluated for CML.

 


Keywords : Chronic Myeloid Leukeima; Imatinib; Major Molecular Response (MMR).
Corresponding Author : Sunita Chhikara